CD47-话题@MedSci

#CD47#

7篇内容 | 2253人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2216044, encodeId=e02c221604416, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a> <a href='/topic/show?id=fd55839636c' target=_blank style='color:#2F92EE;'>#胰腺导管腺癌#</a> <a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a> <a href='/topic/show?id=39f313935c9' target=_blank style='color:#2F92EE;'>#PDAC#</a> <a href='/topic/show?id=2756103612e5' target=_blank style='color:#2F92EE;'>#新辅助免疫治疗#</a>, objectTitle=Nat Commun：“不要吃我”-福建医科大学陈实/田毅峰/王族伟揭示胰腺导管腺癌转移的调控新机制, objectType=article, longId=835418, objectId=7fb2835418a8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220523/1653279468313_2570354.jpg, objectUrl=/article/show_article.do?id=7fb2835418a8, replyNumber=0, likeNumber=129, createdTime=2024-07-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7fb2835418a8, moduleTitle=Nat Commun：“不要吃我”-福建医科大学陈实/田毅峰/王族伟揭示胰腺导管腺癌转移的调控新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fb2835418a8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200691, encodeId=ecd8220069145, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a>, objectTitle=认识CD47，EGFR靶向药联合CD47抗体让靶向药无效的患者重获新生！, objectType=article, longId=822304, objectId=8c75822304d4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-researcher-looking-through-the-microscope-64JFWLH.jpg, objectUrl=/article/show_article.do?id=8c75822304d4, replyNumber=0, likeNumber=82, createdTime=2024-04-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8c75822304d4, moduleTitle=认识CD47，EGFR靶向药联合CD47抗体让靶向药无效的患者重获新生！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c75822304d4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2181171, encodeId=405f21811e1c4, content=<a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a> <a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a> <a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=【Clin Transl Med】赵维莅教授团队证实CD47过表达与DLBCL微环境和进展的关系, objectType=article, longId=808927, objectId=c1e680892e5d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=c1e680892e5d, replyNumber=0, likeNumber=98, createdTime=2024-01-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=c1e680892e5d, moduleTitle=【Clin Transl Med】赵维莅教授团队证实CD47过表达与DLBCL微环境和进展的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e680892e5d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1079278, encodeId=1f9610e927885, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>这个指标相当惊人！<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a>正式进入慢病时代。因为这仅仅是开始，可能接下来会研究PD-L1+ <a href='/topic/show?id=2bd91e444c4' target=_blank style='color:#2F92EE;'>#TIGIT#</a>抗体+化疗，三管其下，效果可能还会进一步提升。也许NSCLC就能被干下来，再往后，还可以考虑与<a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a>单抗结合，从不同角度优化<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>策略，真正开创免疫治疗时代, objectTitle=罗氏PD-L1+TIGIT双靶用于一线NSCLC治疗，效果惊艳，OS死亡风险降低71%, objectType=article, longId=264997, objectId=3fc926499ed5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20211210/c8a587cb92c4451a915488287bad045b.jpg, objectUrl=/article/show_article.do?id=3fc926499ed5, replyNumber=0, likeNumber=267, createdTime=2021-12-12, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fc926499ed5, moduleTitle=罗氏PD-L1+TIGIT双靶用于一线NSCLC治疗，效果惊艳，OS死亡风险降低71%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fc926499ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1051033, encodeId=010b10510339f, content=<a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a>，这个牛, objectTitle=抗CD47 / PD-L1双特异性抗体临床试验：中国首例患者已入组, objectType=article, longId=198679, objectId=2c651986e9a6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202083/1596458780129_5295902.jpeg, objectUrl=/article/show_article.do?id=2c651986e9a6, replyNumber=0, likeNumber=141, createdTime=2021-09-14, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c651986e9a6, moduleTitle=抗CD47 / PD-L1双特异性抗体临床试验：中国首例患者已入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c651986e9a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1051032, encodeId=e19d1051032fc, content=<a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a>, objectTitle=Nat Commun：双重阻断CD47和HER2能消除乳腺癌细胞的放疗抗性, objectType=article, longId=200793, objectId=70b2200e93d1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020916/1600271097443_2467676.PNG, objectUrl=/article/show_article.do?id=70b2200e93d1, replyNumber=0, likeNumber=163, createdTime=2021-09-14, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70b2200e93d1, moduleTitle=Nat Commun：双重阻断CD47和HER2能消除乳腺癌细胞的放疗抗性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70b2200e93d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1051031, encodeId=07cf105103157, content=<a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a>, objectTitle=CD47单克隆抗体初露锋芒！天镜生物多项研发管线产品齐头并进, objectType=article, longId=209745, objectId=fb33209e4510, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202148/1617887320974_2051781.jpg, objectUrl=/article/show_article.do?id=fb33209e4510, replyNumber=0, likeNumber=150, createdTime=2021-09-14, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb33209e4510, moduleTitle=CD47单克隆抗体初露锋芒！天镜生物多项研发管线产品齐头并进, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb33209e4510)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=918533, encodeId=fa4e91853314, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>相关<a href='/topic/show?id=e2a54816ecc' target=_blank style='color:#2F92EE;'>#巨噬细胞#</a>促进<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>浸润转移的机制，近年来这条信号通路十分热，肿瘤相关的巨噬细胞表面核心是<a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a>靶点，这是目前最热的靶点之一了，已有好多临床前的创新药在研发中。, objectTitle=HIF-1α介导肿瘤相关巨噬细胞促进食管鳞癌浸润转移的作用机制研究, objectType=nsfc, longId=874630, objectId=867d8e46302d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/sci/nsfc_show.do?id=867d8e46302d, replyNumber=0, likeNumber=242, createdTime=2021-01-20, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=867d8e46302d, moduleTitle=HIF-1α介导肿瘤相关巨噬细胞促进食管鳞癌浸润转移的作用机制研究, moduleType=nsfc, hrefUrl=https://www.medsci.cn/sci/nsfc_show.do?id=867d8e46302d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=885947, encodeId=877888594e9c, content=<a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a>和<a href='/topic/show?id=e3818e1893' target=_blank style='color:#2F92EE;'>#HER2#</a>在<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>中可能成为明星<a href='/topic/show?id=07a69996557' target=_blank style='color:#2F92EE;'>#靶点#</a>, objectTitle=Nat Commun：双重阻断CD47和HER2能消除乳腺癌细胞的放疗抗性, objectType=article, longId=200793, objectId=70b2200e93d1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020916/1600271097443_2467676.PNG, objectUrl=/article/show_article.do?id=70b2200e93d1, replyNumber=0, likeNumber=275, createdTime=2020-09-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70b2200e93d1, moduleTitle=Nat Commun：双重阻断CD47和HER2能消除乳腺癌细胞的放疗抗性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70b2200e93d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=883034, encodeId=a66d88303407, content=<a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a>成为明星靶点，只要解决红细胞毒性就🐂, objectTitle=高瓴牵头砸进4亿美金，加持天境生物联手艾伯维开发明星靶点CD47, objectType=article, longId=200312, objectId=3baf200312d2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202095/1599312628691_5295905.jpg, objectUrl=/article/show_article.do?id=3baf200312d2, replyNumber=0, likeNumber=220, createdTime=2020-09-06, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3baf200312d2, moduleTitle=高瓴牵头砸进4亿美金，加持天境生物联手艾伯维开发明星靶点CD47, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3baf200312d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CD47

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肝转移# #胰腺导管腺癌# #CD47# #PDAC# #新辅助免疫治疗#

Nat Commun：“不要吃我”-福建医科大学陈实/田毅峰/王族伟揭示胰腺导管腺癌转移的调控新机制

2024-07-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #CD47#

认识CD47，EGFR靶向药联合CD47抗体让靶向药无效的患者重获新生！

2024-04-27发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#CD47# #弥漫性大B细胞淋巴瘤# #DLBCL#

【Clin Transl Med】赵维莅教授团队证实CD47过表达与DLBCL微环境和进展的关系

2024-01-13发表于陕西省

病毒猎手 (审核中...)

前往app查看评论内容

全文收起 #NSCLC#这个指标相当惊人！#肺癌#正式进入慢病时代。因为这仅仅是开始，可能接下来会研究PD-L1+ #TIGIT#抗体+化疗，三管其下，效果可能还会进一步提升。也许NSCLC就能被干下来，再往后，还可以考虑与#CD47#单抗结合，从不同角度优化#免疫治疗#策略，真正开创免疫治疗时代

罗氏PD-L1+TIGIT双靶用于一线NSCLC治疗，效果惊艳，OS死亡风险降低71%

2021-12-12

病毒猎手 (审核中...)

前往app查看评论内容

#CD47#，这个牛

抗CD47 / PD-L1双特异性抗体临床试验：中国首例患者已入组

2021-09-14

病毒猎手 (审核中...)

前往app查看评论内容

#CD47#

Nat Commun：双重阻断CD47和HER2能消除乳腺癌细胞的放疗抗性

2021-09-14

病毒猎手 (审核中...)

前往app查看评论内容

#CD47#

CD47单克隆抗体初露锋芒！天镜生物多项研发管线产品齐头并进

2021-09-14

lifefamily (审核中...)

前往app查看评论内容

#肿瘤#相关#巨噬细胞#促进#食管癌#浸润转移的机制，近年来这条信号通路十分热，肿瘤相关的巨噬细胞表面核心是#CD47#靶点，这是目前最热的靶点之一了，已有好多临床前的创新药在研发中。

HIF-1α介导肿瘤相关巨噬细胞促进食管鳞癌浸润转移的作用机制研究

2021-01-20

智智灵药 (审核中...)

前往app查看评论内容

#CD47#和#HER2#在#乳腺癌#中可能成为明星#靶点#

Nat Commun：双重阻断CD47和HER2能消除乳腺癌细胞的放疗抗性

2020-09-17

lovetcm (审核中...)

前往app查看评论内容

#CD47#成为明星靶点，只要解决红细胞毒性就🐂

高瓴牵头砸进4亿美金，加持天境生物联手艾伯维开发明星靶点CD47

2020-09-06

科室
- - 订阅+
  - 更多科室
工具
服务